Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares remains negative
Q3 FY2026 weighted avg shares was 0 shares, compared with 105.49M shares a year earlier. Trailing-twelve-month weighted avg shares was 79.43M shares. Over 3 fiscal years it compounded at +24.3% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly weighted avg shares holds near 0 shares or moves back toward the trailing-twelve-month quarterly average of 19.86M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 102.93M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +20.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.93M | +11.4% |
| FY2024 | 2024-12-31 | 92.41M | +45.0% |
| FY2023 | 2023-12-31 | 63.72M | +18.9% |
| FY2022 | 2022-12-31 | 53.59M | +8.3% |
| FY2021 | 2021-12-31 | 49.5M | — |
Weighted Avg Shares vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 weighted avg shares of 79.43M shares is the 5th highest of the 10 companies compared; the peer median is 78.18M shares.
- Its year-over-year change of -20.2% is the lowest of 10, against a peer median of +22.5%.
- Over three fiscal years its annual growth of +24.3% compares with a peer median of +23.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 150.19M | +40.8% | +35.2% | |
| LTM Mar 2026 | 102.01M | +6.4% | +6.2% | |
| LTM Mar 2026 | 98.27M | +94.3% | +117.4% | |
| LTM Jun 2026 | 81.93M | +5.6% | +3.5% | |
| LTM Sep 2026 | 79.43M | -20.2% | +24.3% | |
| LTM Mar 2026 | 78.18M | +22.5% | +41.5% | |
| LTM Mar 2026 | 59.6M | +5.0% | +15.0% | |
| LTM Mar 2026 | 49.43M | +35.6% | +23.7% | |
| LTM Mar 2026 | 44.2M | +35.7% | +39.2% | |
| LTM Mar 2026 | 41.5M | +5.9% | +9.8% | |
| Peer median (excluding EWTX) | 78.18M | +22.5% | +23.7% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.